Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IBIO NASDAQ:IMNP NYSE:NNVC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIBIOiBio$0.85+6.8%$0.73$0.56▼$6.89$16.61M0.61.39 million shs945,298 shsIMNPImmune Pharmaceuticals$0.00$0.00▼$0.48$8.14MN/A12.29 million shsN/ANNVCNanoViricides$1.47+1.7%$1.50$0.94▼$2.07$23.55M0.96241,996 shs239,572 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIBIOiBio0.00%+6.72%+7.90%-3.30%-61.03%IMNPImmune Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NNVCNanoViricides0.00%-4.00%-14.29%-19.55%-24.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIBIOiBio1.8277 of 5 stars3.50.00.00.02.50.00.6IMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANNVCNanoViricides0.585 of 5 stars0.05.00.00.01.90.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIBIOiBio 3.00Buy$5.00491.72% UpsideIMNPImmune Pharmaceuticals 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMNP, NNVC, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIBIOiBio$375K44.29N/AN/A$1.41 per share0.60IMNPImmune PharmaceuticalsN/AN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AIMNPImmune PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIBIOiBioN/AN/AN/AN/AN/AIMNPImmune PharmaceuticalsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIBIOiBio0.051.761.76IMNPImmune PharmaceuticalsN/AN/AN/ANNVCNanoViricidesN/A3.442.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIBIOiBio7.90%IMNPImmune Pharmaceuticals1.43%NNVCNanoViricides10.30%Insider OwnershipCompanyInsider OwnershipIBIOiBio0.58%IMNPImmune Pharmaceuticals3.85%NNVCNanoViricides4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIBIOiBio10019.66 million9.82 millionN/AIMNPImmune PharmaceuticalsN/A49.31 millionN/ANot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableIMNP, NNVC, and IBIO HeadlinesRecent News About These CompaniesNanoViricides says antiviral NV-387 may reduce cancer resurgence risk tied to viral infectionsAugust 18, 2025 | proactiveinvestors.comA Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical TrialsAugust 18, 2025 | accessnewswire.comANanoViricides says antiviral candidate NV-387 could address global measles surgeJuly 30, 2025 | proactiveinvestors.comMeasles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricidesJuly 30, 2025 | accessnewswire.comANanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387July 23, 2025 | proactiveinvestors.comNanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive ValueJuly 23, 2025 | accessnewswire.comAMeasles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | usatoday.comNanoViricides says lead antiviral boosted survival in measles-infected miceJuly 21, 2025 | proactiveinvestors.comMeasles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricidesJuly 21, 2025 | accessnewswire.comANanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox diseaseJuly 18, 2025 | pharmabiz.comPWHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | azcentral.comANanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergencyJuly 16, 2025 | proactiveinvestors.comWHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricidesJuly 16, 2025 | accessnewswire.comANanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNanoViricides positioned at forefront of Mpox treatment efforts, says ZacksJuly 15, 2025 | proactiveinvestors.comNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxJuly 15, 2025 | finance.yahoo.comNanoViricides nears completion of clinical trial design for MPox treatmentJuly 14, 2025 | proactiveinvestors.comAdaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricidesJuly 14, 2025 | markets.businessinsider.comNanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health CaseJuly 7, 2025 | theglobeandmail.comNanoViricides advances antiviral candidate NV-387 into Phase 2 trials for MpoxJuly 2, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMNP, NNVC, and IBIO Company DescriptionsiBio NYSE:IBIO$0.84 +0.05 (+6.83%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.Immune Pharmaceuticals NASDAQ:IMNPImmune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.NanoViricides NYSE:NNVC$1.46 +0.03 (+1.74%) As of 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas BJ’s Wholesale Club Pulls Back to Trend: It’s Time for an Entry Super Micro Computer Stock Hasn't Priced in Growth Yet Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Why Zuckerberg's META Sales Look More Bullish Than Bearish 3 Dividend Growth Leaders to Buy Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access